Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Mar 21, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how the body processes certain antibiotics called beta-lactams in patients who are on a life-support machine known as veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This machine is often used for patients experiencing severe heart issues, such as cardiogenic shock or cardiac arrest. The goal of the study is to identify factors that may affect how well these antibiotics work in these critically ill patients, ensuring they receive the right amount to fight infections effectively.
To be eligible for this trial, participants must be patients currently undergoing VA-ECMO and starting a new antibiotic treatment with one of the beta-lactams being studied (like Piperacillin-Tazobactam, Cefepime, or Meropenem). They should also be expected to survive for more than 24 hours and must provide consent, or have someone they trust provide it for them. The study is not yet recruiting participants, but it aims to gather important information that could improve antibiotic treatment for patients on VA-ECMO.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing VA-ECMO
- • Patients requiering initiation of a novel antibiotic therapy with one of the studied beta-lactam (Piperacillin-Tazobactam, Cefepime, or Meropenem) while under VA-ECMO
- • With an expected survival exceeding 24 hours
- • Patient's or their trusted person's consent
- Exclusion Criteria:
- • Subject under administrative or judicial surveillance
- • Non-affiliation to social insurance
- • Pregnant or lactating patient
- • Antibiotic therapy of interest already initiated before VA-ECMO implantation
- • Contraindication to the use of beta-lactam
- • Administration modalities of beta-lactam not compliant with current recommendations
- • Subject in exclusion period from another study
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Clermont Ferrand, , France
Dijon, , France
Paris, , France
Rouen, , France
Patients applied
Trial Officials
ALEXANDRE BEHOUCHE, MD
Principal Investigator
University Hospital, Grenoble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported